NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$48.7m

Last Updated

2021/03/31 22:53 UTC

Data Sources

Company Financials

Executive Summary

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has Cancer Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CGIX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 35% a week.

Volatility Over Time: CGIX's weekly volatility has increased from 27% to 35% over the past year.


Market Performance


7 Day Return

-10.5%

CGIX

-4.8%

US Biotechs

-1.2%

US Market


1 Year Return

69.5%

CGIX

19.3%

US Biotechs

48.3%

US Market

Return vs Industry: CGIX exceeded the US Biotechs industry which returned 44.2% over the past year.

Return vs Market: CGIX matched the US Market which returned 68.8% over the past year.


Shareholder returns

CGIXIndustryMarket
7 Day-10.5%-4.8%-1.2%
30 Day-26.0%0.9%0.2%
90 Day66.4%-13.0%1.6%
1 Year69.5%69.5%21.1%19.3%50.8%48.3%
3 Year-87.7%-87.7%24.2%17.8%62.0%51.9%
5 Year-94.3%-94.3%50.2%38.5%126.9%101.7%

Long-Term Price Volatility Vs. Market

How volatile is Cancer Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cancer Genetics undervalued compared to its fair value and its price relative to the market?

2.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CGIX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CGIX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CGIX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CGIX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CGIX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CGIX is good value based on its PB Ratio (2.4x) compared to the US Biotechs industry average (3.9x).


Future Growth

How is Cancer Genetics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cancer Genetics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cancer Genetics performed over the past 5 years?

30.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CGIX is currently unprofitable.

Growing Profit Margin: CGIX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CGIX is unprofitable, but has reduced losses over the past 5 years at a rate of 30.8% per year.

Accelerating Growth: Unable to compare CGIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.4%).


Return on Equity

High ROE: CGIX has a negative Return on Equity (-87.72%), as it is currently unprofitable.


Financial Health

How is Cancer Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: CGIX's short term assets ($2.8M) do not cover its short term liabilities ($4.8M).

Long Term Liabilities: CGIX's short term assets ($2.8M) exceed its long term liabilities ($134.0K).


Debt to Equity History and Analysis

Debt Level: CGIX is debt free.

Reducing Debt: CGIX has no debt compared to 5 years ago when its debt to equity ratio was 29.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGIX has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CGIX is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Cancer Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CGIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CGIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGIX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Jay Roberts (61 yo)

3yrs

Tenure

US$269,027

Compensation

Mr. John A. Roberts, also known as Jay, MBA has been Chief Executive Officer and President of Cancer Genetics, Inc., since April 30, 2018 and is Principal Financial officer and Principal Accounting officer...


CEO Compensation Analysis

Compensation vs Market: Jay's total compensation ($USD269.03K) is below average for companies of similar size in the US market ($USD513.72K).

Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CGIX's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: CGIX's board of directors are considered experienced (9.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 403%.


Top Shareholders

Company Information

Cancer Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cancer Genetics, Inc.
  • Ticker: CGIX
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$48.692m
  • Shares outstanding: 10.56m
  • Website: https://www.cancergenetics.com

Number of Employees


Location

  • Cancer Genetics, Inc.
  • 201 Route 17 North
  • 2nd Floor
  • Rutherford
  • New Jersey
  • 7070
  • United States

Listings


Biography

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and im...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/31 22:53
End of Day Share Price2021/03/30 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.